Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01175590 · ClinicalTrials.gov registry record · Phase 3
Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle
A Phase 3 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 518
- Enrollment target
NCT01175590 is a Phase 3 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 518 participants.
The verdict
NCT01175590, a Phase 3 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 518 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety of Besivance (besifloxacin ophthalmic suspension, 0.6%) compared to vehicle.
Interventions
- DRUG Vehicle
- DRUG Besivance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 518 participants |
| Start Date | 2010-06 |
| Est. Completion | 2012-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01175590
The ClinicalTrials.gov registry entry for NCT01175590 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 518 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT01175590 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01175590 about?
NCT01175590 is a clinical study titled "Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle". The objective of this study is to evaluate the safety of Besivance (besifloxacin ophthalmic suspension, 0.6%) compared to vehicle.
What is the current status of trial NCT01175590?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 518 participants. The study started on 2010-06. Estimated completion is 2012-02.
What interventions are being tested in trial NCT01175590?
The interventions under investigation include: Vehicle (DRUG), Besivance (DRUG).
Who is sponsoring clinical trial NCT01175590?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.